Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMNDNASDAQ:SONNNASDAQ:TRVNNASDAQ:TTNP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMNDClearmind Medicine$0.86+2.4%$0.97$0.80▼$2.30$3.59M0.91858,776 shs12,636 shsSONNSonnet BioTherapeutics$1.17+0.4%$1.26$1.08▼$10.02$3.67M0.94386,124 shs268,368 shsTRVNTrevena$1.14$1.15$0.95▼$10.75$1.09M0.632,088 shs44 shsTTNPTitan Pharmaceuticals$4.34-1.5%$4.27$3.03▼$14.80$4.02M1.3138,572 shs464 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMNDClearmind Medicine+2.14%-3.41%-17.31%-26.50%-30.08%SONNSonnet BioTherapeutics+0.43%-0.44%-11.07%-18.53%-23.86%TRVNTrevena0.00%+12.87%-5.00%-13.64%-87.13%TTNPTitan Pharmaceuticals-0.57%-4.93%-1.92%+21.09%-37.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMNDClearmind Medicine1.2275 of 5 stars0.05.00.00.02.61.70.0SONNSonnet BioTherapeutics3.6307 of 5 stars3.55.00.00.02.50.00.0TRVNTrevena1.8382 of 5 stars3.05.00.00.00.60.00.6TTNPTitan Pharmaceuticals0.6805 of 5 stars0.05.00.00.02.20.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMNDClearmind Medicine 0.00N/AN/AN/ASONNSonnet BioTherapeutics 3.00Buy$20.001,616.74% UpsideTRVNTrevena 2.00Hold$5.00338.60% UpsideTTNPTitan Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TRVN, TTNP, CMND, and SONN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/7/2025SONNSonnet BioTherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/28/2025SONNSonnet BioTherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMNDClearmind MedicineN/AN/AN/AN/A$0.54 per shareN/ASONNSonnet BioTherapeutics$20K184.65N/AN/A($0.71) per share-1.64TRVNTrevena$443K2.47N/AN/A($11.07) per share-0.10TTNPTitan Pharmaceuticals$180K21.92N/AN/A$2.67 per share1.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMNDClearmind Medicine-$5.26M-$1.10N/A∞N/AN/A-164.79%-71.12%N/ASONNSonnet BioTherapeutics-$7.44MN/A0.00∞N/AN/A-777.92%-271.32%8/13/2025 (Estimated)TRVNTrevena-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%8/6/2025 (Estimated)TTNPTitan Pharmaceuticals-$4.71M-$4.59N/A∞N/AN/A-145.92%-129.20%8/13/2025 (Estimated)Latest TRVN, TTNP, CMND, and SONN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/12/2025Q2 2025CMNDClearmind MedicineN/A-$0.16N/A-$0.16N/AN/A5/14/2025Q1 2025TTNPTitan PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/A5/13/2025Q2 2025SONNSonnet BioTherapeutics-$0.92-$0.89+$0.03-$0.89N/AN/A3/20/2025Q4 2024TTNPTitan PharmaceuticalsN/A-$0.85N/A-$0.85N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMNDClearmind MedicineN/AN/AN/AN/AN/ASONNSonnet BioTherapeuticsN/AN/AN/AN/AN/ATRVNTrevenaN/AN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMNDClearmind MedicineN/A1.741.74SONNSonnet BioTherapeuticsN/A1.031.03TRVNTrevenaN/A2.422.42TTNPTitan PharmaceuticalsN/A7.737.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMNDClearmind Medicine96.05%SONNSonnet BioTherapeutics9.45%TRVNTrevena13.56%TTNPTitan Pharmaceuticals31.49%Insider OwnershipCompanyInsider OwnershipCMNDClearmind MedicineN/ASONNSonnet BioTherapeutics2.00%TRVNTrevena2.70%TTNPTitan Pharmaceuticals0.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMNDClearmind MedicineN/A4.27 millionN/ANot OptionableSONNSonnet BioTherapeutics103.17 million3.10 millionNot OptionableTRVNTrevena40959,000841,000OptionableTTNPTitan Pharmaceuticals10910,000907,000OptionableTRVN, TTNP, CMND, and SONN HeadlinesRecent News About These Companiestitan pharmaceuticals issues common stock following preferred stock conversionsJune 4, 2025 | investing.comTitan announces filing of registration statement for proposed combinationJune 4, 2025 | finance.yahoo.comTitan Pharmaceuticals, Inc. Files Registration Statement for Proposed Merger with TalenTec Sdn. Bhd.June 3, 2025 | quiverquant.comTitan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.June 3, 2025 | globenewswire.comTitan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred StockApril 11, 2025 | globenewswire.comTitan Pharmaceuticals: Q4 Earnings SnapshotMarch 20, 2025 | sfgate.comTitan Pharmaceuticals receives Nasdaq notice of non-complianceNovember 27, 2024 | markets.businessinsider.comTitan Pharmaceuticals Faces Nasdaq Compliance Challenges with Reporting and Audit Committee RequirementsNovember 27, 2024 | quiverquant.comTitan Pharmaceuticals, Inc. Announces Receipt of Notice from NasdaqNovember 27, 2024 | globenewswire.comSanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly BeatOctober 25, 2024 | msn.comTitan Pharmaceuticals, Inc. (TTNP)October 17, 2024 | finance.yahoo.com(TTNP) Technical Pivots with Risk ControlsSeptember 25, 2024 | news.stocktradersdaily.comWhen (TTNP) Moves Investors should ListenSeptember 15, 2024 | news.stocktradersdaily.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, FRZA, TTNP on Behalf of ShareholdersSeptember 9, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, CFB, TTNP, DFS on Behalf of ShareholdersSeptember 5, 2024 | stockhouse.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. – TTNPSeptember 5, 2024 | globenewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. - TTNPSeptember 4, 2024 | prnewswire.comTitan Pharmaceuticals Share Price (TTNP.US)August 24, 2024 | lse.co.ukShareholder Alert: Ademi LLP investigates whether Titan Pharmaceuticals, Inc. has obtained a Fair Price for its Public ShareholdersAugust 23, 2024 | prnewswire.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Titan Pharmaceuticals, Inc. MergerAugust 22, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRVN, TTNP, CMND, and SONN Company DescriptionsClearmind Medicine NASDAQ:CMND$0.86 +0.02 (+2.38%) Closing price 06/18/2025 03:48 PM EasternExtended Trading$0.85 -0.01 (-1.28%) As of 06/18/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Sonnet BioTherapeutics NASDAQ:SONN$1.16 +0.01 (+0.43%) Closing price 06/18/2025 03:59 PM EasternExtended Trading$1.20 +0.04 (+3.43%) As of 06/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.Trevena NASDAQ:TRVN$1.14 0.00 (0.00%) As of 06/17/2025Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.Titan Pharmaceuticals NASDAQ:TTNP$4.34 -0.07 (-1.48%) Closing price 06/18/2025 03:53 PM EasternExtended Trading$4.36 +0.02 (+0.55%) As of 06/18/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
